3920-37-4

Basic information

• Product Name: 2,5-DIMETHYL-4-NITRO-2 H-PYRAZOLE-3-CARBOXYLIC ACID
• Synonyms: 1,3-MIMETHYL-4-NITRO-1H-PYRAZOLE-5-CARBOXYLIC ACID;1,3-DIMETHYL-4-NITRO-1H-PYRAZOLE-5-CARBOXYLIC ACID;2,5-DIMETHYL-4-NITRO-2 H-PYRAZOLE-3-CARBOXYLIC ACID
• CAS NO: 3920-37-4
• Molecular Formula: C₆H₇N₃O₄
• Molecular Weight: 185.14
• Product Categories: Pyrazole
• Mol File: 3920-37-4.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 379.432 °C at 760 mmHg
• Flash Point: 183.274 °C
• Appearance: /
• Density: 1.619 g/cm³
• CAS DataBase Reference: 2,5-DIMETHYL-4-NITRO-2 H-PYRAZOLE-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-DIMETHYL-4-NITRO-2 H-PYRAZOLE-3-CARBOXYLIC ACID(3920-37-4)
• EPA Substance Registry System: 2,5-DIMETHYL-4-NITRO-2 H-PYRAZOLE-3-CARBOXYLIC ACID(3920-37-4)

Safety Data

• Hazardous Substances Data: 3920-37-4(Hazardous Substances Data)

Usage

General Description

2,5-Dimethyl-4-nitro-2 H-pyrazole-3-carboxylic acid is a chemical compound with the molecular formula C7H8N4O4. It is a yellow solid with a molecular weight of 212.16 g/mol. This chemical is used in the synthesis and production of pharmaceuticals and agrochemicals. It is also used as a building block in the preparation of various organic compounds. 2,5-Dimethyl-4-nitro-2 H-pyrazole-3-carboxylic acid has potential applications in the field of medicine and agriculture.

Upstream product

• 5744-56-9 1,3-dimethylpyrazol-5-carboxylic acid 
• 78208-69-2 methyl 1,3-dimethyl-4-nitro-1H-pyrazole-5-carboxylate 
• 67208-10-0 4-iodo-2,5-dimethyl-2H-pyrazole-3-carboxylic acid 
• 5744-40-1 ethyl 1,3-dimethylpyrazole-5-carboxylate 
• 615-79-2 ethyl 2,4-diketopentanoate 

Downstream Products

• 37141-71-2 1,3-dimethyl-4-nitro-1H-pyrazole-5-carbonyl chloride 
• 159427-64-2 (2S)-N-<(1,3-dimethyl-4-nitropyrazol-5-yl)carbonyl>pyrrolidine-2-carboxaldehyde diethyl thioacetal 
• 868392-50-1 4-amino-N,1,3-trimethyl-N-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-1H-pyrazole-5-carboxamide 
• 868392-49-8 N,1,3-trimethyl-N-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-4-nitro-1H-pyrazole-5-carboxamide 
• 1025830-72-1 (4-Amino-2,5-dimethyl-2H-pyrazol-3-yl)-[(S)-2-(bis-ethylsulfanyl-methyl)-pyrrolidin-1-yl]-methanone 
• 59023-32-4 1,3-Dimethyl-4-aminopyrazole-5-carboxamide 
• 78208-58-9 1,3-dimethyl-4-nitropyrazole-5-carboxamide 
• 104393-31-9 1,3-dimethyl-5-phenylpyrazolo<4,3-d>pyrimidin-7-one 
• 104393-22-8 1,3-Dimethyl-5-pyridin-3-yl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one 
• 104393-30-8 1,3-Dimethyl-5-pyridin-4-yl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one 
• 104393-24-0 1,3-Dimethyl-5-p-tolyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one 
• 104393-21-7 5-Benzyl-1,3-dimethyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one 
• 104393-23-9 5-(4-Chloro-phenyl)-1,3-dimethyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one 
• 104393-47-7 N-(5-Carbamoyl-1,3-dimethyl-1H-pyrazol-4-yl)-nicotinamide 

Relevant articles and documents

SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS

The present application relates to substituted fused heteroaryl and heterocyclic compounds, useful as nicotinamide adenine dinucleotide phosphate oxidase inhibitors (NADPH oxidase inhibitors), processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by NADPH oxidase. (Formula I)

N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

The present invention relates to compounds of Formula I: wherein R1, R2, R3, A1, A2, A3, A4, Y1 and Y2 and D have the meaning described herein. The present invention also relates to pharmaceutical compositions comprising such compounds and therapeutic uses thereof.

Synthesis and antitumor activity of a new class of pyrazolo[4,3- e]pyrrolo[1,2-a][1,4]diazepinone analogues of pyrrolo[1,4][2,1- c]benzodiazepines

A new class of pyrrolo[1,4]benzodiazepine (PBD) analogues featuring a pyrazolo[4,3-e]pyrrolo[1,2-a][1,4]diazepinone ring system has been designed and synthesized. These compounds, 2a-o, are characterized by the substitution of the aromatic A ring, characteristic of the PBDs, with a disubstituted pyrazole ring bearing alkyl and benzyl substituents at N6 or N7 and alkyl or carbomethoxy substituents at C8. Biological evaluation revealed an appreciable in vitro cytotoxic activity for compounds 2a,b,f-i.